Both neuropsychiatric disorders and malignancies of central nervous system (CNS) represent a significant
health burden and life-threatening diseases worldwide. Radiotracer-based neuroimaging is an attractive tool that permits
the in vivo detection and characterization of metabolic and molecular processes which are fundamental elements for brain
function, and improves the theranostics of brain diseases and disorders.
In this review, we outlined the new development of molecular imaging probes for dopamine and serotonin systems in neuropsychiatry
and boron neutron capture therapy (BNCT) for brain tumors in neuro-oncology with positron emission tomography
(PET) and single-photon emission computed tomography (SPECT).